LAUNCHING THE CAMPAIGN FOR ACCESS TO AFFORDABLE LENALIDOMIDE

Lenalidomide

Lenalidomide

Minister Mkhize must ensure access to cancer medicine that WHO now considers “essential”

Johannesburg (9 July 2019) — It was announced today that lenalidomide, a lifesaving medicine to treat multiple myeloma, has been included on the latest edition of the World Health Organisation’s (WHO) Essential Medicines List (EML).

Welcoming the inclusion of lenalidomide on the list, among 5 new cancer medicines, the Fix the Patent Laws campaign (a coalition of nearly 45 patient advocacy groups in South Africa) said the announcement offers new Health Minister Dr Zwelini Mkhize an historic opportunity to act to save lives.

“Currently, the majority of cancer patients in South Africa who could benefit from lenalidomide cannot access it due to its prohibitively high cost of ZAR R60,781 per patient per month, or ZAR 729,372 per patient for a year’s course—depriving many people of a chance at life,” said Salomé Meyer, from the Cancer Alliance.

Please read more at .http://bit.ly/2NRLxIu

Related Articles

Related

CELGENE FLAGGED

For overpricing bone marrow cancer drug The Competition Commission has referred for prosecution to the Competition Tribunal (“Tribunal”), international drug manufacturer Celgene Corporation (“Celgene Corp”) and its subsidiary Celgene Logistics S.a.r.l (“Celgene...

read more

Cancer Alliance tackles price gouging

Represented by SECTION27, takes on multinational company Cancer Alliance tackles price gouging 14 November 2024, Johannesburg - The Cancer Alliance, represented by SECTION27, has been admitted by the Competition Tribunal as an intervening party in the excessive...

read more